Insurance savings "strengthen system":
This article was originally published in Clinica
German health minister Ulla Schmidt said that the Euro4bn ($4.7bn) surplus achieved by the statutory sickness finds last year was a tribute to the system's new efficiency since the health reform of early 2004. The associated savings of Euro9-10bn also meant that decision-makers could build more quality into the system. Additionally, it meant that average public contributions to the funds did not have to increase. They are currently at 14.2%. Ms Schmidt had earlier talked of a rise to some 15%.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.